BAK-free latanoprost: safe and effective
The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at the Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria.
The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at this year's Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria.
Professor Christophe Baudouin, of the Quinze-Vingts National Ophthalmology Hospital, Paris, France investigated the ocular surface toxicity of Nova21027 and compared the results with those of a BAK-containing anti-glaucoma eye drop.
Nova21027, which is stable at room temperature, demonstrated both safety and efficacy. The formula was found to have reduced ocular surface toxicity compared with the BAK-containing drops: it was well tolerated and did not damage the ocular surface under conditions of stress.
Novagali will present more data on Nova21027 at the 2009 meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, Florida in May.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
